Laparoscopic Device Market by Product (Access Devices, Energy Systems, Instruments), Usage (Disposable, Reusable), End User, Application - Global Forecast 2025-2032
Description
The Laparoscopic Device Market was valued at USD 18.69 billion in 2024 and is projected to grow to USD 20.14 billion in 2025, with a CAGR of 7.63%, reaching USD 33.67 billion by 2032.
Comprehensive introduction to the evolving laparoscopic device landscape and the strategic clinical, operational, and commercial forces influencing adoption
Minimally invasive surgery has matured into a core pillar of modern procedural care, and laparoscopic devices remain central to delivering improved patient outcomes while reducing length of stay and surgical morbidity. Advances in optics, energy delivery, and instrument ergonomics have progressively raised the capabilities of laparoscopic approaches, enabling complex interventions across specialties that were once the exclusive domain of open surgery. At the same time, shifts in care settings toward ambulatory and outpatient facilities have created new demand patterns and commercial considerations for device makers and health systems.
In the current environment, device developers, procurement leaders, and clinical teams must weigh clinical efficacy, total cost of ownership, and system interoperability when selecting technologies. Training and human factors continue to shape adoption curves, and regulatory scrutiny on safety and device traceability has increased. As a result, stakeholders who align product design with real-world clinical workflows and demonstrate measurable value through evidence generation position themselves to capture durable adoption. The following executive summary synthesises the strategic landscape, highlighting the key forces that will define competitive advantage in the near to medium term.
In-depth exploration of transformative clinical, technological, and operational shifts that are reshaping device adoption, workflows, and procurement strategies
The landscape of laparoscopic care is undergoing multiple concurrent transformations that are technological, clinical, and operational in nature. Technologically, high-definition and 3D visualization systems paired with enhanced energy platforms are improving precision and reducing operative time, while integration with adjunct imaging and navigation tools is enhancing intraoperative decision-making. Clinically, surgeons increasingly adopt single-port and reduced-port techniques where feasible, and hybrid approaches that combine laparoscopic access with adjunctive minimally invasive tools have become more common. These trends drive demand for modular, interoperable devices that fit a variety of procedural needs.
Operationally, hospitals and ambulatory sites are optimizing throughput and cost structures. This focus is accelerating interest in disposable instruments that reduce reprocessing burdens as well as reusable systems that promise lower lifecycle costs in high-volume settings. Concurrently, workforce dynamics and training pathways influence device choice; remote proctoring and simulation-based credentialing are enabling faster, safer adoption of novel tools. Finally, sustainability concerns and supply chain resilience have gained prominence, prompting manufacturers and providers to explore packaging reductions, material substitutions, and localised sourcing to balance environmental goals with clinical performance.
Comprehensive assessment of how the 2025 United States tariff adjustments have reshaped supply chain decisions, sourcing strategies, and procurement negotiations across the device value chain
Policy changes in tariff regimes can materially influence the economics and sourcing strategies of medical device supply chains. The cumulative effects of tariff changes enacted in 2025 have prompted manufacturers and purchasing organisations to reassess where and how components and finished goods are sourced. As a direct consequence, companies have evaluated options such as dual sourcing, nearshoring production, and modifying bill-of-materials to prioritise materials and parts that face lower tariff exposure. Procurement teams have increased emphasis on contract clauses that account for tariff variability and on inventory strategies that mitigate short-term price fluctuations.
Beyond sourcing adjustments, tariffs have altered commercial negotiations and product design choices. Suppliers have sought opportunities to redesign components to use alternate materials or consolidate assemblies to reduce cross-border content that attracts higher duties. Smaller specialised manufacturers, in particular, have experienced tighter margins and in some cases accelerated conversations around partnerships or contract manufacturing to spread fixed costs. Meanwhile, health systems have responded by intensifying total cost of ownership assessments and by pursuing longer-term supply agreements to stabilise pricing. Taken together, these dynamics underscore the importance of supply chain agility, transparent supplier cost structures, and proactive policy scenario planning for industry participants.
Actionable segmentation insights across product architectures, surgical applications, end users, and usage models that inform product roadmaps and commercial prioritisation
A nuanced view of segmentation clarifies where clinical need, purchase behavior, and innovation potential intersect within the laparoscopic ecosystem. From a product perspective, the market encompasses access devices such as ports and trocars, energy systems spanning advanced bipolar, electrosurgical, and ultrasonic platforms, a wide array of hand instruments including dissectors, forceps, graspers, retractors, and scissors, insufflators that predominantly rely on carbon dioxide, retrieval devices, and visualization systems that integrate cameras, laparoscopes, light sources, and monitors. Within access devices, ports are categorised into disposable and reusable options, while trocars are distinguished between bladed and bladeless designs; such distinctions influence clinical preference, reprocessing requirements, and procurement cycles.
Application-based segmentation further refines targeting by highlighting clinical specialties with differing procedural volumes and device requirements, including bariatric, cardiothoracic, colorectal, general, gynecological, and urological surgeries. End-user segmentation identifies distinct purchasing environments-ambulatory surgical centers, clinics, and hospitals-each with unique procurement processes, space and staffing constraints, and cost-per-procedure expectations. Finally, the usage model dichotomy between disposable and reusable devices continues to drive competing narratives around infection control, lifecycle cost, environmental impact, and operational throughput. Understanding these layered segmentation lenses enables more precise product roadmaps and commercial strategies that align to the specific needs of clinical stakeholders.
Key regional strategic considerations and clinical adoption dynamics across the Americas, Europe Middle East and Africa, and Asia Pacific markets that influence commercial execution
Regional dynamics shape both clinical uptake and commercial strategy for laparoscopic devices in distinct ways. In the Americas, a mature market environment is characterised by advanced clinical infrastructure, diverse care settings, and strong uptake of outpatient surgical models. Procurement decisions in this region frequently weigh evidence-based performance against bundled pricing and service models, and regulatory and reimbursement pathways incentivise innovations that demonstrably reduce length of stay or complication rates. Elsewhere, Latin American markets display heterogeneous adoption driven by public procurement cycles, import duties, and local manufacturing capacity.
In the Europe, Middle East and Africa region, country-level variation in reimbursement and purchasing structures influences device selection and adoption speed. Many healthcare systems emphasise cost containment and centralised purchasing, encouraging manufacturers to demonstrate clear value propositions and to offer flexible commercial models. Meanwhile, sterilisation infrastructure and reprocessing standards vary by country, affecting the viability of reusable instruments versus disposables. In the Asia-Pacific region, high procedure volumes, rapid investments in hospital infrastructure, and a growing focus on domestic manufacturing are key drivers. Hospitals in several countries prioritise scalable solutions that support high-throughput workflows, while policy incentives and tariff considerations influence localisation strategies and partnerships with regional suppliers.
Focused company-level insights that illuminate strategic positioning, partnership models, and innovation trajectories among leaders and challengers in the device ecosystem
Competitive dynamics in the laparoscopic device space reflect a mix of legacy medtech incumbents, specialised niche innovators, and agile startups that often partner with OEMs or contract manufacturers to scale production. Incumbent firms typically compete on breadth of portfolio, integrated systems, and established service networks, whereas smaller entrants differentiate through product innovation, focused clinical evidence, and lower-cost manufacturing techniques. Collaboration strategies-ranging from co-development agreements to distribution partnerships-have become central to accelerating time-to-market and accessing new clinical channels.
Across the industry, a clear segmentation of strategic focus areas has emerged: investment in enhanced visualization and imaging, development of advanced energy platforms, expansion of single-use instrument portfolios, and introduction of interoperable systems that simplify OR integration. Companies are also extending offerings beyond hardware to include education, training, and value-based service contracts that align incentives with clinical outcomes. This combination of product innovation and service orientation is reshaping competitive positioning and creating opportunities for cross-sector partnerships that blend clinical expertise, software capabilities, and manufacturing scale.
Practical and tactical recommendations for device manufacturers and healthcare leaders to accelerate adoption, strengthen supply chains, and align commercial models with clinical value
Industry leaders can take several practical steps to accelerate adoption, reduce operational friction, and protect margins in a dynamic environment. First, prioritise user-centered product development that integrates clinician feedback early and iteratively; solutions that reduce cognitive load and streamline workflows secure faster clinical acceptance. Second, build robust evidence programs that combine clinical studies, real-world data, and health economics analyses to substantiate claims around safety, efficiency, and cost-effectiveness. Third, diversify manufacturing and sourcing strategies to mitigate tariff exposure and supply disruptions by evaluating nearshoring, dual sourcing, and flexible contract manufacturing relationships.
In addition, align commercial models with customer needs by offering flexible pricing, service bundles, and training packages that support adoption across ambulatory centers, clinics, and hospital systems. Invest in digital tools that enhance post-sale engagement such as remote monitoring, simulation-based training, and teleproctoring to shorten the learning curve. Finally, adopt sustainability-minded design and packaging choices where feasible, and proactively engage with payers and regulators to clarify value pathways. Taken together, these actions will strengthen competitive differentiation while reducing operational risk and improving the likelihood of durable clinical integration.
Rigorous research methodology and evidence synthesis approach incorporating primary expert interviews, secondary literature review, and iterative validation steps
The research underpinning this executive summary synthesises evidence from a structured methodology that combines primary qualitative inquiry, comprehensive secondary research, and iterative validation. Primary inputs included interviews with practicing surgeons across specialties, procurement and supply chain leaders, clinical engineers, and senior executives with direct responsibility for product strategy. These conversations provided frontline insight into device preferences, procedural workflows, and procurement constraints. Secondary research drew on peer-reviewed clinical literature, regulatory guidance, product technical specifications, and publicly available health system reports to contextualise clinical efficacy and policy environments.
To ensure analytical rigor, the study team triangulated findings across multiple data sources and applied a standardized framework to categorise device functions, clinical applications, end-user needs, and usage models. Sensitivity checks and expert peer review sessions were conducted to surface potential biases and to refine interpretation. Limitations were acknowledged where data availability varied by region or where rapid policy changes, such as tariff adjustments, introduced emerging variables. The methodology emphasises transparency in source attribution and replicable analytical steps to support confident decision-making by stakeholders.
Concise conclusion synthesising strategic imperatives for stakeholders aiming to navigate the evolving laparoscopic device environment and capture clinical value
The evolution of laparoscopic care presents both clear opportunities and pragmatic challenges for device manufacturers, health systems, and clinical teams. Technological advances in visualization and energy delivery, coupled with operational imperatives to improve throughput and reduce complications, continue to drive innovation. At the same time, policy shifts, such as tariff adjustments, and regional differences in procurement and reimbursement require companies to be agile in sourcing, pricing, and commercial engagement. Stakeholders that balance clinical performance with lifecycle economics, and that invest in clinician training and evidence generation, will create durable adoption pathways.
Moving forward, success will depend on an integrated approach that aligns product design with real-world workflow constraints, leverages partnerships to scale production and distribution, and continuously demonstrates value to both clinicians and payers. Strategic investments in supply chain resilience, modular system architectures, and services that reduce adoption friction will provide competitive advantage. In sum, the next phase of growth in the laparoscopic device ecosystem will favor organisations that combine technical excellence with operational discipline and customer-centric commercial models.
Please Note: PDF & Excel + Online Access - 1 Year
Comprehensive introduction to the evolving laparoscopic device landscape and the strategic clinical, operational, and commercial forces influencing adoption
Minimally invasive surgery has matured into a core pillar of modern procedural care, and laparoscopic devices remain central to delivering improved patient outcomes while reducing length of stay and surgical morbidity. Advances in optics, energy delivery, and instrument ergonomics have progressively raised the capabilities of laparoscopic approaches, enabling complex interventions across specialties that were once the exclusive domain of open surgery. At the same time, shifts in care settings toward ambulatory and outpatient facilities have created new demand patterns and commercial considerations for device makers and health systems.
In the current environment, device developers, procurement leaders, and clinical teams must weigh clinical efficacy, total cost of ownership, and system interoperability when selecting technologies. Training and human factors continue to shape adoption curves, and regulatory scrutiny on safety and device traceability has increased. As a result, stakeholders who align product design with real-world clinical workflows and demonstrate measurable value through evidence generation position themselves to capture durable adoption. The following executive summary synthesises the strategic landscape, highlighting the key forces that will define competitive advantage in the near to medium term.
In-depth exploration of transformative clinical, technological, and operational shifts that are reshaping device adoption, workflows, and procurement strategies
The landscape of laparoscopic care is undergoing multiple concurrent transformations that are technological, clinical, and operational in nature. Technologically, high-definition and 3D visualization systems paired with enhanced energy platforms are improving precision and reducing operative time, while integration with adjunct imaging and navigation tools is enhancing intraoperative decision-making. Clinically, surgeons increasingly adopt single-port and reduced-port techniques where feasible, and hybrid approaches that combine laparoscopic access with adjunctive minimally invasive tools have become more common. These trends drive demand for modular, interoperable devices that fit a variety of procedural needs.
Operationally, hospitals and ambulatory sites are optimizing throughput and cost structures. This focus is accelerating interest in disposable instruments that reduce reprocessing burdens as well as reusable systems that promise lower lifecycle costs in high-volume settings. Concurrently, workforce dynamics and training pathways influence device choice; remote proctoring and simulation-based credentialing are enabling faster, safer adoption of novel tools. Finally, sustainability concerns and supply chain resilience have gained prominence, prompting manufacturers and providers to explore packaging reductions, material substitutions, and localised sourcing to balance environmental goals with clinical performance.
Comprehensive assessment of how the 2025 United States tariff adjustments have reshaped supply chain decisions, sourcing strategies, and procurement negotiations across the device value chain
Policy changes in tariff regimes can materially influence the economics and sourcing strategies of medical device supply chains. The cumulative effects of tariff changes enacted in 2025 have prompted manufacturers and purchasing organisations to reassess where and how components and finished goods are sourced. As a direct consequence, companies have evaluated options such as dual sourcing, nearshoring production, and modifying bill-of-materials to prioritise materials and parts that face lower tariff exposure. Procurement teams have increased emphasis on contract clauses that account for tariff variability and on inventory strategies that mitigate short-term price fluctuations.
Beyond sourcing adjustments, tariffs have altered commercial negotiations and product design choices. Suppliers have sought opportunities to redesign components to use alternate materials or consolidate assemblies to reduce cross-border content that attracts higher duties. Smaller specialised manufacturers, in particular, have experienced tighter margins and in some cases accelerated conversations around partnerships or contract manufacturing to spread fixed costs. Meanwhile, health systems have responded by intensifying total cost of ownership assessments and by pursuing longer-term supply agreements to stabilise pricing. Taken together, these dynamics underscore the importance of supply chain agility, transparent supplier cost structures, and proactive policy scenario planning for industry participants.
Actionable segmentation insights across product architectures, surgical applications, end users, and usage models that inform product roadmaps and commercial prioritisation
A nuanced view of segmentation clarifies where clinical need, purchase behavior, and innovation potential intersect within the laparoscopic ecosystem. From a product perspective, the market encompasses access devices such as ports and trocars, energy systems spanning advanced bipolar, electrosurgical, and ultrasonic platforms, a wide array of hand instruments including dissectors, forceps, graspers, retractors, and scissors, insufflators that predominantly rely on carbon dioxide, retrieval devices, and visualization systems that integrate cameras, laparoscopes, light sources, and monitors. Within access devices, ports are categorised into disposable and reusable options, while trocars are distinguished between bladed and bladeless designs; such distinctions influence clinical preference, reprocessing requirements, and procurement cycles.
Application-based segmentation further refines targeting by highlighting clinical specialties with differing procedural volumes and device requirements, including bariatric, cardiothoracic, colorectal, general, gynecological, and urological surgeries. End-user segmentation identifies distinct purchasing environments-ambulatory surgical centers, clinics, and hospitals-each with unique procurement processes, space and staffing constraints, and cost-per-procedure expectations. Finally, the usage model dichotomy between disposable and reusable devices continues to drive competing narratives around infection control, lifecycle cost, environmental impact, and operational throughput. Understanding these layered segmentation lenses enables more precise product roadmaps and commercial strategies that align to the specific needs of clinical stakeholders.
Key regional strategic considerations and clinical adoption dynamics across the Americas, Europe Middle East and Africa, and Asia Pacific markets that influence commercial execution
Regional dynamics shape both clinical uptake and commercial strategy for laparoscopic devices in distinct ways. In the Americas, a mature market environment is characterised by advanced clinical infrastructure, diverse care settings, and strong uptake of outpatient surgical models. Procurement decisions in this region frequently weigh evidence-based performance against bundled pricing and service models, and regulatory and reimbursement pathways incentivise innovations that demonstrably reduce length of stay or complication rates. Elsewhere, Latin American markets display heterogeneous adoption driven by public procurement cycles, import duties, and local manufacturing capacity.
In the Europe, Middle East and Africa region, country-level variation in reimbursement and purchasing structures influences device selection and adoption speed. Many healthcare systems emphasise cost containment and centralised purchasing, encouraging manufacturers to demonstrate clear value propositions and to offer flexible commercial models. Meanwhile, sterilisation infrastructure and reprocessing standards vary by country, affecting the viability of reusable instruments versus disposables. In the Asia-Pacific region, high procedure volumes, rapid investments in hospital infrastructure, and a growing focus on domestic manufacturing are key drivers. Hospitals in several countries prioritise scalable solutions that support high-throughput workflows, while policy incentives and tariff considerations influence localisation strategies and partnerships with regional suppliers.
Focused company-level insights that illuminate strategic positioning, partnership models, and innovation trajectories among leaders and challengers in the device ecosystem
Competitive dynamics in the laparoscopic device space reflect a mix of legacy medtech incumbents, specialised niche innovators, and agile startups that often partner with OEMs or contract manufacturers to scale production. Incumbent firms typically compete on breadth of portfolio, integrated systems, and established service networks, whereas smaller entrants differentiate through product innovation, focused clinical evidence, and lower-cost manufacturing techniques. Collaboration strategies-ranging from co-development agreements to distribution partnerships-have become central to accelerating time-to-market and accessing new clinical channels.
Across the industry, a clear segmentation of strategic focus areas has emerged: investment in enhanced visualization and imaging, development of advanced energy platforms, expansion of single-use instrument portfolios, and introduction of interoperable systems that simplify OR integration. Companies are also extending offerings beyond hardware to include education, training, and value-based service contracts that align incentives with clinical outcomes. This combination of product innovation and service orientation is reshaping competitive positioning and creating opportunities for cross-sector partnerships that blend clinical expertise, software capabilities, and manufacturing scale.
Practical and tactical recommendations for device manufacturers and healthcare leaders to accelerate adoption, strengthen supply chains, and align commercial models with clinical value
Industry leaders can take several practical steps to accelerate adoption, reduce operational friction, and protect margins in a dynamic environment. First, prioritise user-centered product development that integrates clinician feedback early and iteratively; solutions that reduce cognitive load and streamline workflows secure faster clinical acceptance. Second, build robust evidence programs that combine clinical studies, real-world data, and health economics analyses to substantiate claims around safety, efficiency, and cost-effectiveness. Third, diversify manufacturing and sourcing strategies to mitigate tariff exposure and supply disruptions by evaluating nearshoring, dual sourcing, and flexible contract manufacturing relationships.
In addition, align commercial models with customer needs by offering flexible pricing, service bundles, and training packages that support adoption across ambulatory centers, clinics, and hospital systems. Invest in digital tools that enhance post-sale engagement such as remote monitoring, simulation-based training, and teleproctoring to shorten the learning curve. Finally, adopt sustainability-minded design and packaging choices where feasible, and proactively engage with payers and regulators to clarify value pathways. Taken together, these actions will strengthen competitive differentiation while reducing operational risk and improving the likelihood of durable clinical integration.
Rigorous research methodology and evidence synthesis approach incorporating primary expert interviews, secondary literature review, and iterative validation steps
The research underpinning this executive summary synthesises evidence from a structured methodology that combines primary qualitative inquiry, comprehensive secondary research, and iterative validation. Primary inputs included interviews with practicing surgeons across specialties, procurement and supply chain leaders, clinical engineers, and senior executives with direct responsibility for product strategy. These conversations provided frontline insight into device preferences, procedural workflows, and procurement constraints. Secondary research drew on peer-reviewed clinical literature, regulatory guidance, product technical specifications, and publicly available health system reports to contextualise clinical efficacy and policy environments.
To ensure analytical rigor, the study team triangulated findings across multiple data sources and applied a standardized framework to categorise device functions, clinical applications, end-user needs, and usage models. Sensitivity checks and expert peer review sessions were conducted to surface potential biases and to refine interpretation. Limitations were acknowledged where data availability varied by region or where rapid policy changes, such as tariff adjustments, introduced emerging variables. The methodology emphasises transparency in source attribution and replicable analytical steps to support confident decision-making by stakeholders.
Concise conclusion synthesising strategic imperatives for stakeholders aiming to navigate the evolving laparoscopic device environment and capture clinical value
The evolution of laparoscopic care presents both clear opportunities and pragmatic challenges for device manufacturers, health systems, and clinical teams. Technological advances in visualization and energy delivery, coupled with operational imperatives to improve throughput and reduce complications, continue to drive innovation. At the same time, policy shifts, such as tariff adjustments, and regional differences in procurement and reimbursement require companies to be agile in sourcing, pricing, and commercial engagement. Stakeholders that balance clinical performance with lifecycle economics, and that invest in clinician training and evidence generation, will create durable adoption pathways.
Moving forward, success will depend on an integrated approach that aligns product design with real-world workflow constraints, leverages partnerships to scale production and distribution, and continuously demonstrates value to both clinicians and payers. Strategic investments in supply chain resilience, modular system architectures, and services that reduce adoption friction will provide competitive advantage. In sum, the next phase of growth in the laparoscopic device ecosystem will favor organisations that combine technical excellence with operational discipline and customer-centric commercial models.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
198 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence and machine learning for real-time intraoperative imaging guidance in laparoscopic surgery
- 5.2. Development of single-port laparoscopic systems designed to minimize patient trauma and accelerate recovery
- 5.3. Advancements in robot-assisted laparoscopic platforms to enhance surgeon dexterity and procedural precision
- 5.4. Increasing adoption of advanced energy devices such as ultrasonic shears and vessel sealers for superior hemostasis control
- 5.5. Emergence of augmented reality overlays coupled with laparoscopic video to improve anatomical visualization
- 5.6. Growth of disposable laparoscopic instrument portfolios aimed at reducing infection risks and operating room turnaround times
- 5.7. Design evolution toward ergonomic laparoscopic instrument handles to alleviate surgeon fatigue during lengthy procedures
- 5.8. Miniaturization of laparoscopic instruments to enable complex microsurgical and pediatric interventions
- 5.9. Integration of intraoperative fluorescence imaging systems for real-time vascular and biliary anatomy identification
- 5.10. Rise of tele‐operated laparoscopic surgery solutions facilitating remote procedures in underserved healthcare regions
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Laparoscopic Device Market, by Product
- 8.1. Access Devices
- 8.1.1. Ports
- 8.1.1.1. Disposable
- 8.1.1.2. Reusable
- 8.1.2. Trocars
- 8.1.2.1. Bladed
- 8.1.2.2. Bladeless
- 8.2. Energy Systems
- 8.2.1. Advanced Bipolar
- 8.2.2. Electrosurgical
- 8.2.3. Ultrasonic
- 8.3. Instruments
- 8.3.1. Dissectors
- 8.3.2. Forceps
- 8.3.3. Graspers
- 8.3.4. Retractors
- 8.3.5. Scissors
- 8.4. Insufflators
- 8.5. Retrieval Devices
- 8.6. Visualization Systems
- 8.6.1. Cameras
- 8.6.2. Laparoscopes
- 8.6.3. Light Sources
- 8.6.4. Monitors
- 9. Laparoscopic Device Market, by Usage
- 9.1. Disposable
- 9.2. Reusable
- 10. Laparoscopic Device Market, by End User
- 10.1. Ambulatory Surgical Centers
- 10.2. Clinics
- 10.3. Hospitals
- 11. Laparoscopic Device Market, by Application
- 11.1. Bariatric Surgery
- 11.2. Cardiothoracic Surgery
- 11.3. Colorectal Surgery
- 11.4. General Surgery
- 11.5. Gynecological Surgery
- 11.6. Urological Surgery
- 12. Laparoscopic Device Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Laparoscopic Device Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Laparoscopic Device Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Medtronic plc
- 15.3.2. Ethicon
- 15.3.3. Stryker Corporation
- 15.3.4. Karl Storz SE & Co. KG
- 15.3.5. Olympus Corporation
- 15.3.6. B. Braun Melsungen AG
- 15.3.7. Intuitive Surgical, Inc.
- 15.3.8. CONMED Corporation
- 15.3.9. Becton, Dickinson and Company
- 15.3.10. Richard Wolf GmbH
- 15.3.11. Smith & Nephew plc
- 15.3.12. Boston Scientific Corporation
- 15.3.13. Cook Medical
- 15.3.14. Microline Surgical, Inc.
- 15.3.15. Peters Surgical
- 15.3.16. Mindray Medical International Limited
- 15.3.17. Applied Medical Resources Corporation
- 15.3.18. Teleflex Incorporated
- 15.3.19. SCHÖLLY Fiberoptic GmbH
- 15.3.20. Richard Wolf GmbH
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
